| scholarly article | Q13442814 |
| P50 | author | Kristina Kirschner | Q50068106 |
| P2093 | author name string | David W. Melton | |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 3223-3232 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Anticancer Research | Q326290 |
| P1476 | title | Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs | |
| P478 | volume | 30 |
| Q82603453 | A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer |
| Q52822011 | A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight. |
| Q36803539 | A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer |
| Q39012252 | ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency |
| Q39199269 | Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population |
| Q38276429 | Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? |
| Q29616694 | Cancer drug resistance: an evolving paradigm |
| Q30416926 | Cis-acting polymorphisms affect complex traits through modifications of microRNA regulation pathways |
| Q33798999 | Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions |
| Q53072244 | Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation. |
| Q49981106 | DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade |
| Q27022940 | DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy |
| Q92916364 | Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer |
| Q55286515 | Distinct roles of XPF-ERCC1 and Rad1-Rad10-Saw1 in replication-coupled and uncoupled inter-strand crosslink repair. |
| Q33702497 | Drugging the Cancers Addicted to DNA Repair |
| Q92571019 | ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers |
| Q36175526 | ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis |
| Q33634975 | ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy |
| Q36107000 | Fluorescence-based incision assay for human XPF-ERCC1 activity identifies important elements of DNA junction recognition |
| Q60916341 | Function and Interactions of ERCC1-XPF in DNA Damage Response |
| Q37459590 | Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer |
| Q37108536 | High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer |
| Q41297799 | High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer |
| Q37688903 | Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. |
| Q82500401 | Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome |
| Q90661538 | Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy |
| Q28547840 | MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells |
| Q34897598 | MicroRNA gene dosage alterations and drug response in lung cancer |
| Q48124027 | Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. |
| Q42541262 | Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma |
| Q36740692 | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. |
| Q64981692 | Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. |
| Q34343749 | Potential role for the Metnase transposase fusion gene in colon cancer through the regulation of key genes |
| Q45953377 | Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy. |
| Q38908367 | Recruitment and positioning determine the specific role of the XPF-ERCC1 endonuclease in interstrand crosslink repair. |
| Q34842777 | Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. |
| Q33698685 | Sumoylation of the Rad1 nuclease promotes DNA repair and regulates its DNA association |
| Q59136910 | The Influence of Metabolism on Drug Response in Cancer |
| Q90357642 | Tissue specificity of DNA damage response and tumorigenesis |
| Q28115910 | USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses |
| Q32182056 | Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. |
| Q38805489 | Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells |
| Q34484477 | Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology |
| Q60049551 | rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer |
| Q36224427 | γ-secretase inhibition combined with cisplatin enhances apoptosis of nasopharyngeal carcinoma cells |
Search more.